Patents by Inventor Waldemar Priebe

Waldemar Priebe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8648102
    Abstract: The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as kinase inhibitors, cause the downregulation of c-myc, and inhibit the growth and survival of cancerous cell lines.
    Type: Grant
    Filed: January 13, 2012
    Date of Patent: February 11, 2014
    Assignee: Board of Regents, The University of Texas System
    Inventors: Waldemar Priebe, Nicholas Donato, Moshe Talpaz, Slawomir Szymanski, Izabela Fokt, Alexander Levitzki
  • Patent number: 8637675
    Abstract: Pyridine compounds effective in modulation STAT3 and/or STAT5 activation are provided that are useful in the prevention and treatment of proliferative disease and conditions including cancer, inflammation and proliferative skin disorders.
    Type: Grant
    Filed: February 21, 2012
    Date of Patent: January 28, 2014
    Assignee: Board of Regents, The University of Texas System
    Inventors: Waldemar Priebe, Stanislaw Skora, Timothy Madden, Izabela Fokt, Charles Conrad
  • Publication number: 20130244986
    Abstract: Embodiments of the invention generally relate to pharmaceutical compositions containing at least one caffeic acid compound and methods for the topical treatment of proliferative and inflammatory skin disorders such as plaque psoriasis, atopic dermatitis, and other disorders. In some embodiments, the topical treatment includes applications of the pharmaceutical composition containing at least one caffeic acid compound or a mixture of caffeic acid compounds such as caffeic acid ester compounds, caffeic acid amide compounds, analogues thereof, derivatives thereof, salts thereof, or mixtures thereof. The pharmaceutical composition or topical dosage may contain the caffeic acid compound at a concentration by weight within a range from about 0.01% to about 20%, preferably, from about 0.1% to about 15%, preferably, from about 1% to about 10%, more preferably, from about 3% to about 7%, and more preferably, from about 4% to about 6%.
    Type: Application
    Filed: April 26, 2013
    Publication date: September 19, 2013
    Applicant: Moleculin LLC
    Inventors: Waldemar Priebe, Charles Conrad, Timothy Madden
  • Patent number: 8450337
    Abstract: Embodiments of the invention generally relate to pharmaceutical compositions containing at least one caffeic acid compound and methods for the topical treatment of proliferative and inflammatory skin disorders such as plaque psoriasis, atopic dermatitis, and other disorders. In some embodiments, the topical treatment includes applications of the pharmaceutical composition containing at least one caffeic acid compound or a mixture of caffeic acid compounds such as caffeic acid ester compounds, caffeic acid amide compounds, analogues thereof, derivatives thereof, salts thereof, or mixtures thereof. The pharmaceutical composition or topical dosage may contain the caffeic acid compound at a concentration by weight within a range from about 0.01% to about 20%, preferably, from about 0.1% to about 15%, preferably, from about 1% to about 10%, more preferably, from about 3% to about 7%, and more preferably, from about 4% to about 6%.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: May 28, 2013
    Assignee: Moleculin, LLC
    Inventors: Waldemar Priebe, Charles Conrad, Timothy Madden
  • Publication number: 20130129675
    Abstract: Methods of modulating the INF-induced STAT3 activation in a patient in need-thereof are provided for the treatment of disease. The methods comprise the step of administrating to a patient the combination of a therapeutically effective amount of interferon including INF-? and/or INF-? in combination with a STAT3 inhibitor.
    Type: Application
    Filed: December 4, 2010
    Publication date: May 23, 2013
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Waldemar Priebe, Amy Heimberger, Izabela Fokt, Jayakmuar Arumugam, Ling-Yuan Kong, Timothy Madden, Charles Conrad
  • Publication number: 20120276108
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of glycolysis, inhibitors of protein glycosylation, anti-virals, and down-regulators of insulin receptor and IGF-1 receptor for the treatment or prevention of inflammatory dermatological diseases or proliferative dermatological diseases.
    Type: Application
    Filed: January 11, 2012
    Publication date: November 1, 2012
    Applicant: INTERTECH BIO
    Inventor: Waldemar Priebe
  • Patent number: 8299033
    Abstract: Methods of treating glioblastoma and pancreatic cancer are provided by the administration of a therapeutically effective amount of a iodo-hexose compound to a subject in need thereof. The subject disclosure includes methods of treating glioblastoma and pancreatic cancer comprising the administration of a therapeutically effective amount of a 2-deoxy-2-iodo-D-hexose compound including 2-deoxy-2-iodo-D-mannose, 2-deoxy-2-iodo-D-glucose, 2-deoxy-2-iodo-D-galactose, and/or 2-deoxy-2-iodo-D-talose to a subject in need thereof.
    Type: Grant
    Filed: October 19, 2009
    Date of Patent: October 30, 2012
    Assignee: Board of Regents, The University of Texas System
    Inventors: Waldemar Priebe, Slawomir Szymanski, Izabela Fokt, Charles Conrad, Timothy Madden
  • Patent number: 8252740
    Abstract: Elastin-like polypeptide (ELP) serves as a vector for thermally-targeted delivery of therapeutics, including cytotoxic chemotherapeutic drugs such as doxorubicin. Examples of an ELP-based delivery vehicle can comprise: (1) a cell penetrating peptide, such as a Tat peptide, (2) ELP, and (3) the lysosomally degradable glycylphenylalanylleucylglycine (GFLG) (SEQ ID NO: 3) spacer and a cysteine residue (SEQ ID NO: 4) conjugated to therapeutic such as doxorubicin, or an analog thereof.
    Type: Grant
    Filed: January 29, 2007
    Date of Patent: August 28, 2012
    Assignee: The University of Mississippi Medical Center
    Inventors: Drazen Raucher, Gene Bidwell, III, Waldemar Priebe, Izabela Fokt
  • Publication number: 20120214850
    Abstract: The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as kinase inhibitors, cause the downregulation of c-myc, and inhibit the growth and survival of cancerous cell lines.
    Type: Application
    Filed: January 13, 2012
    Publication date: August 23, 2012
    Inventors: Waldemar Priebe, Nicholas Donato, Moshe Talpaz, Slawomir Szymanski, Izabela Fokt, Alexander Levitzki
  • Publication number: 20120149738
    Abstract: Pyridine compounds effective in modulation STAT3 and/or STAT5 activation are provided that are useful in the prevention and treatment of proliferative disease and conditions including cancer, inflammation and proliferative skin disorders.
    Type: Application
    Filed: February 21, 2012
    Publication date: June 14, 2012
    Applicant: Board of Regents, The University of Texas System
    Inventors: Waldemar Priebe, Stanislaw Skora, Timothy Madden, Izabela Fokt, Charles Conrad
  • Patent number: 8143412
    Abstract: Pyridine compounds effective in modulation STAT3 and/or STAT5 activation are provided that are useful in the prevention and treatment of proliferative disease and conditions including cancer, inflammation and proliferative skin disorders.
    Type: Grant
    Filed: June 26, 2009
    Date of Patent: March 27, 2012
    Inventors: Waldemar Priebe, Stanislaw Skora, Timothy Madden, Izabela Fokt, Charles Conrad
  • Patent number: 8119827
    Abstract: The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as kinase inhibitors, cause the downregulation of c-myc, and inhibit the growth and survival of cancerous cell lines.
    Type: Grant
    Filed: June 28, 2010
    Date of Patent: February 21, 2012
    Assignee: Board of Regents, The University of Texas System
    Inventors: Waldemar Priebe, Nicholas Donato, Moshe Talpaz, Slawomir Szymanski, Izabela Fokt, Alexander Levitzki
  • Publication number: 20110275577
    Abstract: The present invention relates to caffeic acid analog compounds and methods which may be useful for regeneration, cellular programming, and the treatment of dermatologic, gynecologic, and genital diseases such as inflammatory dermatologic conditions, dysplasia, neoplasia, in situ carcinoma, invasive carcinoma, lichen sclerosus, lichen planus, vaginal dysplasia, vaginal carcinoma, vulvar dysplasia, vulvar carcinoma, cervical dysplasia, cervical carcinoma, and Kaposi's sarcoma.
    Type: Application
    Filed: January 10, 2011
    Publication date: November 10, 2011
    Applicant: Moleculin, LLC
    Inventors: Anna Priebe, Waldemar Priebe
  • Publication number: 20110160151
    Abstract: Novel compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are provided herein.
    Type: Application
    Filed: June 25, 2009
    Publication date: June 30, 2011
    Inventors: Waldemar Priebe, Marcin Cybulski, Izabela Fokt, Stanislaw Skora, Charles Conrad, Timothy Madden
  • Patent number: 7928062
    Abstract: Methods are disclosed for inhibiting or disrupting Janus tyrosine kinase 3 (Jak3) dependent function in cells of lymphoid or myeloid origin, especially for blocking proliferation and function of lymphocytes (e.g., T-cells, B-cells). A Mannich base compound, or a derivative or modified compound, is employed which is capable of selectively inhibiting Jak3 while affecting other protein tyrosine kinase activities to a lesser extent or not at all, to provide beneficial effects such as mitigation of transplant rejection and alleviation of allergic responses with fewer side effects than with conventional immunosuppressive agents.
    Type: Grant
    Filed: November 5, 2007
    Date of Patent: April 19, 2011
    Assignee: Board of Regents of the University of Texas System
    Inventors: Robert A. Kirken, Barry D. Kahan, Stanislaw M. Stepkowski, Waldemar Priebe, Izabela Fokt, Szymon Kosinski
  • Publication number: 20110053992
    Abstract: Pyridine compounds effective in modulation STAT3 and/or STAT5 activation are provided that are useful in the prevention and treatment of proliferative disease and conditions including cancer, inflammation and proliferative skin disorders.
    Type: Application
    Filed: June 26, 2009
    Publication date: March 3, 2011
    Inventors: Waldemar Priebe, Stanislaw Skora, Timothy Madden, Izabela Fokt, Charles Conrad
  • Publication number: 20110021805
    Abstract: The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as kinase inhibitors, cause the downregulation of c-myc, and inhibit the growth and survival of cancerous cell lines.
    Type: Application
    Filed: June 28, 2010
    Publication date: January 27, 2011
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Waldemar Priebe, Nicholas Donato, Moshe Talpaz, Slawomir Szymanski, Izabela Fokt, Alexander Levitzki
  • Publication number: 20110003758
    Abstract: Provided herein are methods of treating brain tumors by administering a therapeutically effective amount of a compound of the Formulas I or II to a patient in need thereof.
    Type: Application
    Filed: March 2, 2009
    Publication date: January 6, 2011
    Inventors: Waldemar Priebe, Charles Conrad, Timothy Madden, Izabela Fokt, Slawomir Szymanski, Leposava Antonovic
  • Patent number: 7745468
    Abstract: The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as kinase inhibitors, cause the downregulation of c-myc, and inhibit the growth and survival of cancerous cell lines.
    Type: Grant
    Filed: December 13, 2004
    Date of Patent: June 29, 2010
    Assignee: Board of Regents, University of Texas Systems The
    Inventors: Waldemar Priebe, Nicholas Donato, Moshe Talpaz, Slawomir Szymanski, Izabela Fokt, Alexander Levitzki
  • Publication number: 20100152121
    Abstract: Methods of treating glioblastoma and pancreatic cancer are provided by the administration of a therapeutically effective amount of a iodo-hexose compound to a subject in need thereof. The subject disclosure includes methods of treating glioblastoma and pancreatic cancer comprising the administration of a therapeutically effective amount of a 2-deoxy-2-iodo-D-hexose compound including 2-deoxy-2-iodo-D-mannose, 2-deoxy-2-iodo-D-glucose, 2-deoxy-2-iodo-D-galactose, and/or 2-deoxy-2-iodo-D-talose to a subject in need thereof.
    Type: Application
    Filed: October 19, 2009
    Publication date: June 17, 2010
    Inventors: Waldemar Priebe, Slawomir Szymanski, Izabela Fokt, Charles Conrad, Timothy Madden